top of page
In the context of the PRAISE e-cohort, we listed here scientific articles about OASI. This list is regularly updated.
Last update: January 29th, 2020
Search
Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing[...]
S. Jamal et al., 2020. Immune checkpoint inhibitors have revolutionized cancer therapy by blocking inhibitory pathways of the immune...
Feb 1, 2020
Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy
Kostine M et al., 2019 Compared with conventional cancer therapies, the spectrum of toxicities observed with checkpoint inhibitors is...
Dec 9, 2019
Testing Immune-Related Adverse Events in Cancer Immunotherapy
JR. Farmer, 2019. Immune-targeted therapeutics are being used in cancer. Immune "checkpoint inhibition" provides promise for prolonged...
Oct 4, 2019
Balancing cancer immunotherapy and immune-related adverse events: The emerging role [...]
T. Alissafi et al., 2019 Advances in our understanding οf tumor immunity have prompted a paradigm shift in oncology, with the emergence...
Aug 15, 2019
Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard [...]
Couey M.A et al., 2019 Background: The risk of delayed autoimmunity occurring months or years after discontinuation of immunotherapy is...
Jul 3, 2019
Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis
Salem JE et al., 2019 Immune checkpoint inhibitors are broadly active treatments for cancer, but they can result in immune-related...
Jun 13, 2019
Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with RA
Gottenberg JE et al., 2019 Objective To compare the effectiveness and safety of three non-tumour necrosis factor (TNF) α inhibitors...
Jan 24, 2019
Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists?
Kostine M et al., 2019 Cancer immunotherapy blocking immune checkpoints represents a major advance in oncology. Immune checkpoint...
Jan 18, 2019
Impact of Baseline Steroids on Efficacy of Programmed CellDeath-1 and Programmed Death-Ligand 1 ...
Purpose Treatment with programmed cell death-1 or programmed death ligand 1 (PD-(L)1) inhibitors is now standard therapy for patients...
Aug 20, 2018
Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-Review From the Mela [...]
Kristina Buder-Bakhaya et al., 2018 Background: Immune checkpoint inhibition (ICI) with anti-CTLA-4 and/or anti-PD-1 antibodies is...
Jun 28, 2018
Cost of inpatient admissions for immune-related adverse effects from immune checkpoint [...]
JN. Chu et al., 2018. Immune checkpoint inhibitors such as anti-CTLA4 and anti-PD1 antibodies represent a paradigm shift in the treatment...
Jun 1, 2018
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
JJ. Moslehi, JE. Salem, JA. Sosman, B. Lebrun-Vignes, DB. Johnson, 2018. Immune checkpoint inhibitors have greatly improved clinical...
Mar 10, 2018
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer
K. Haratani et al., 2018. Importance Immune-related adverse events (irAEs) have been associated with the efficacy of PD-1 (programmed...
Mar 1, 2018
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint [...]
J.R Brahmer et al., 2018. Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of...
Feb 14, 2018
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
M.A Postow, R. Sidlow, M.D Hellmann, 2018. The wide range of immune-related adverse effects associated with immune checkpoint blockade...
Jan 11, 2018
Clinical features, predictive correlates, and pathophysiology of immune-related adverse events[...]
Jennifer M Yoest, 2017. Abstract: Identification and characterization of T-cell regulatory mechanisms, or checkpoints, have led to a wave...
Oct 10, 2017
Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor [...]
Belkhir R et al., 2017 Objectives: Immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte-associated protein 4 and...
Jun 9, 2017
Opportunistic autoimmunity secondary to cancer immunotherapy(OASI): An emerging challenge
M. Kostine, L. Chiche, E. Lazaro, P. Halfon, C. Charpin, D. Arniaud, F. Retornaz, P. Blanco, N. Jourde-Chiche, C. Richez, C. Stavris,...
Feb 15, 2017
Neurologic complications of immune checkpoint inhibitors
AF. Hottinger, 2016. In recent years, advances in the understanding of the regulatory mechanisms of the immune system has led to the...
Dec 1, 2016
The Safety of Therapeutic Monoclonal Antibodies: Implications for Cancer Therapy [...]
R. Demlova et al., 2016. Monoclonal antibody-based treatment of cancer has been established as one of the most successful therapeutic...
Oct 24, 2016
bottom of page